Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

, and timing of VITAL-1 and VITAL-2 and other clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, patents, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Susan Ferris

Investor Relations

650-266-3200


'/>"/>
SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Silicon Valley Bank, the bank of the ... that examines the merger, acquisition and IPO activity of ... the annual report based on 2013 data, venture investment ... started tracking the data in 2005. "2013 ... healthcare M&A activity over the last few years, the ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)...   Medical Equipment Solutions, Corp. are pleased ... of Defense (US Army) contract valued at over $2 ... diagnostic machine and technical support staffing. As an 8-A ... Business Administration (SBA), Medical Equipment is proud to support ... medical diagnostic equipment. The SBA 8-A certification is a ...
Breaking Medicine Technology:Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... GREENWOOD VILLAGE, Colo. , July 21 Ampio Pharmaceuticals, Inc. ... clinical trial of Optina™ for the treatment of diabetic macular edema, an ... vision loss in patients with diabetes mellitus. , ... Ampio Pharmaceuticals has completed a formal agreement with ...
... Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. ... contract from the U.S. Army to develop an investigational device ... deployed to the Army under a separate contract. Under the ... of the Signal-X6 system that will incorporate automated heart sound ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™ 2Zargis Awarded U.S. Army Contract 2Zargis Awarded U.S. Army Contract 3
(Date:7/30/2014)... 2014 Effective today, the wellness ... Highmark Blue Cross Blue Shield Insurance. Owned by ... Nourish Nutrition and Health opened for business earlier ... Wexford. , The basis of the services ... informing clients on the simplicity of leading a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 A ... business and technology startups is now available from ... marketing agency based in the Chicago region. The ... software and information technology (IT), services, ecommerce, healthcare, ... , Marketing disciplines critical to startup success include ...
(Date:7/30/2014)... Printing whole new organs for transplants sounds like something ... technology could one day make actual kidneys, livers, hearts ... In the ACS journal Langmuir , scientists are ... that takes them a step closer to realizing their ... , Yong Huang and colleagues note that this idea ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The 3D ... seen and touched in our new 50,000 square foot ... (just behind Target). , Projectorscreenstore.com is one of the ... range of sophisticated technology and Audio/Visual products for education, ... with Makerbot, the leading manufacturer of 3D printers for ...
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
Breaking Medicine News(10 mins):Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3
... in the topoisomerase II alpha ( TOP2A ) gene ... compared with non-anthracycline-based regimens, according to a study in ... of the National Cancer Institute. The increased responsiveness ... tumors carry an amplification of the HER 2 ...
... Health & Science University Knight Cancer Institute will evaluate ... Seattle, Wash.) is as effective in delivering highly precise ... it has been in those with prostate cancer. , ... for prostate cancer, and it is our hope to ...
... Senior Living, Inc. (NYSE: SRZ ) today ... its Bank Credit Facility, which eliminates all financial covenants, ... 2009 maturity date."We are very pleased that our bank ... through its maturity date," said Mark Ordan, Sunrise,s chief ...
... NSAIDs can cause liver or stomach illness in ... (HealthDay News) -- Many over-the-counter painkillers and fever ... the potential danger of liver damage and stomach ... will have to include these warnings on all ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... Smithfield Foods, Inc. (NYSE: SFD ) ... no clinical signs or symptoms of the presence of ... its employees at its joint ventures in Mexico. As ... officials and are submitting samples from their swine herds ...
Cached Medicine News:Health News:Gene alterations associated with response to anthracycline therapy for breast cancer 2Health News:OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 3Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 4Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
5L...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: